恒瑞医药：子公司SHR-4685注射液临床试验获批

财中社07-07 17:10

　　7月7日，恒瑞医药（600276/01276）发布公告，公司子公司苏州盛迪亚生物医药有限公司近日收到国家药品监督管理局核准签发的关于SHR-4685注射液的《药物临床试验批准通知书》，将于近期开展临床试验。

　　该药物是公司自主研发的创新型抗肿瘤药物，拟用于治疗晚期实体瘤，目前国内外尚无同类药物获批上市。截止目前SHR-4685注射液的相关项目累计研发投入约为1940万元（未经审计）。

　　2026年一季度，恒瑞医药实现收入81.41亿元，归母净利润22.82亿元。

（文章来源：财中社）

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2649898554?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-07-07 17:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2649898554","market":"sh","top_or_hot":-1,"title":"恒瑞医药：子公司SHR-4685注射液临床试验获批","media":"财中社","content":"<html><body><div>\n<p>　　7月7日，<span><a href=\"https://laohu8.com/S/600276\">恒瑞医药</a></span>（600276/01276）发布公告，公司子公司苏州盛迪亚生物医药有限公司近日收到国家药品监督管理局核准签发的关于SHR-4685注射液的《药物临床试验批准通知书》，将于近期开展临床试验。</p><p>　　该药物是公司自主研发的创新型抗肿瘤药物，拟用于治疗晚期实体瘤，目前国内外尚无同类药物获批上市。截止目前SHR-4685注射液的相关项目累计研发投入约为1940万元（未经审计）。</p><p>　　2026年一季度，<span href=\"http://quote.eastmoney.com/unify/r/116.01276\" target=\"_blank\" web=\"1\"><a href=\"https://laohu8.com/S/01276\">恒瑞医药</a></span>实现收入81.41亿元，归母净利润22.82亿元。</p><p>（文章来源：财中社）</p> </div></body></html>","source":"stock_eastmoney","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>恒瑞医药：子公司SHR-4685注射液临床试验获批</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n恒瑞医药：子公司SHR-4685注射液临床试验获批\n</h2>\n\n<h4 class=\"meta\">\n\n</h4>\n\n</header>\n<article>\n<html><body><div>\n<p>　　7月7日，<span><a href=\"https://laohu8.com/S/600276\">恒瑞医药</a></span>（600276/01276）发布公告，公司子公司苏州盛迪亚生物医药有限公司近日收到国家药品监督管理局核准签发的关于SHR-4685注射液的《药物临床试验批准通知书》，将于近期开展临床试验。</p><p>　　该药物是公司自主研发的创新型抗肿瘤药物，拟用于治疗晚期实体瘤，目前国内外尚无同类药物获批上市。截止目前SHR-4685注射液的相关项目累计研发投入约为1940万元（未经审计）。</p><p>　　2026年一季度，<span href=\"http://quote.eastmoney.com/unify/r/116.01276\" target=\"_blank\" web=\"1\"><a href=\"https://laohu8.com/S/01276\">恒瑞医药</a></span>实现收入81.41亿元，归母净利润22.82亿元。</p><p>（文章来源：财中社）</p> </div></body></html>\n\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"http://finance.eastmoney.com/a/202607073796801870.html\">财中社</a> </p>\n\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n</div>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1146622755.USD","symbol_name":"安本中国A股股票基金A Acc","start_time":0,"source_url":"http://finance.eastmoney.com/a/202607073796801870.html","article_id":"2649898554","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2649898554","pubTimestamp":1783415400,"columns":[],"sourceInfo":{"source_id":"stock_eastmoney","name":"东方财富"},"weMediaInfo":null,"summary":"7月7日，恒瑞医药（600276/01276）发布公告，公司子公司苏州盛迪亚生物医药有限公司近日收到国家药品监督管理局核准签发的关于SHR-4685注射液的《药物临床试验批准通知书》，将于近期开展临床试验。该药物是公司自主研发的创新型抗肿瘤药物，拟用于治疗晚期实体瘤，目前国内外尚无同类药物获批上市。","collect":0,"end_time":0,"defaultTopTitle":"eastmoney.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600276":"恒瑞医药","LU1146622755.USD":"安本中国A股股票基金A Acc","LU0405327494.USD":"ALLSPRING CHINA A FOCUS \"I\" (USD) ACC","BK0060":"抗癌","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","IBBQ":"Invesco Nasdaq Biotechnology ETF","LU1820825898.SGD":"Aberdeen Standard SICAV I - China A Share Equity A Acc SGD-H","LU1655091616.SGD":"JPMorgan Funds - China A-Share Opportunities A (acc) SGD","LU0359201612.USD":"贝莱德中国基金A2","BK0196":"行业龙头","LU1580142542.USD":"Blackrock Systematic China A-Share Opportunities A2 USD","LU2289578879.USD":"ALLIANZ CHINA A OPPORTUNITIES \"AT\" (USD) ACC","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","BK0239":"医药制造","LU1997245177.USD":"安联神洲A股基金","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU1023057109.AUD":"BGF CHINA \"A2\" (AUDHDG) ACC","01276":"恒瑞医药","LU2580892789.USD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (USD) ACC","LU1255011170.USD":"JPM CHINA A-SHARE OPPORTUNITIES \"A\" (USD) ACC","LU0405327148.USD":"ALLSPRING CHINA A FOCUS \"A\" (USD) ACC","LU1781817850.SGD":"Blackrock Systematic China A-Share Opportunities A2 SGD-H","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU2543165471.USD":"E FUND (HK) GLOBAL QUALITY GROWTH \"A\" (USD) ACC","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","BK0183":"MSCI概念","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","BK0188":"融资融券","LU1997244956.HKD":"ALLIANZ CHINA A-SHARES \"AT\" (HKD) ACC A","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","BMED":"iShares Health Innovation Active ETF","BK0012":"证金概念","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","LU2580892862.HKD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (HKD) ACC","BK0028":"国家队","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","LU2495084118.USD":"ALLIANZ CHINA A-SHARES \"ATH\" (USDHDG) ACC","LU0359201885.HKD":"BGF CHINA \"A2\" (HKD) ACC","BK1191":"制药"},"translate_title":"Hengrui Medicine: Subsidiary SHR-4685 Injection Clinical Trial Approved","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600276":1.5,"01276":1.5,"IBBQ":1.5,"BMED":1.5},"content_text":"7月7日，恒瑞医药（600276/01276）发布公告，公司子公司苏州盛迪亚生物医药有限公司近日收到国家药品监督管理局核准签发的关于SHR-4685注射液的《药物临床试验批准通知书》，将于近期开展临床试验。　　该药物是公司自主研发的创新型抗肿瘤药物，拟用于治疗晚期实体瘤，目前国内外尚无同类药物获批上市。截止目前SHR-4685注射液的相关项目累计研发投入约为1940万元（未经审计）。　　2026年一季度，恒瑞医药实现收入81.41亿元，归母净利润22.82亿元。（文章来源：财中社）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2649898554","isCrawlerRequest":true}